The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis.

Histology ISUP grade group PSMA PET/CT Prostate cancer

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 19 01 2024
accepted: 10 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: aheadofprint

Résumé

To assess if PSMA PET quantitative parameters are associated with pathologic ISUP grade group (GG) and upgrading/downgrading. PCa patients undergoing radical prostatectomy with or without pelvic lymph node dissection staged with preoperative PSMA PET at seven referral centres worldwide were evaluated. PSMA PET parameters which included SUV A total of 605 patients were included. Overall, 2%, 37%, 37%, 10% and 13% patients had pathologic ISUP GG1, 2, 3, 4, and 5, respectively. At multivariable analyses, all three parameters SUV Quantitative PSMA PET parameters are associated with surgical ISUP GG and upgrading. We propose clinically relevant thresholds of these parameters which can improve in PCa risk stratification in daily clinical practice.

Identifiants

DOI: 10.1007/s00259-024-06847-y PMID: 39088067
pubmed: 39088067
doi: 10.1007/s00259-024-06847-y
pii: 10.1007/s00259-024-06847-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, et al. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. J Urol. 2020;203:537–45. https://doi.org/10.1097/JU.0000000000000531 .
doi: 10.1097/JU.0000000000000531 pubmed: 31487220
Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, et al. Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Eur J Nucl Med Mol Imaging. 2021;48:509–20. https://doi.org/10.1007/s00259-020-04974-w .
doi: 10.1007/s00259-020-04974-w pubmed: 32789599
Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7:1635–42. https://doi.org/10.1001/jamaoncol.2021.3771 .
doi: 10.1001/jamaoncol.2021.3771 pubmed: 34529005 pmcid: 8446902
Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Kusters-Vandevelde HVN, Wijers CHW, et al. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Eur J Nucl Med Mol Imaging. 2022;49:3929–37. https://doi.org/10.1007/s00259-022-05827-4 .
doi: 10.1007/s00259-022-05827-4 pubmed: 35543733
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7 .
doi: 10.1016/S0140-6736(20)30314-7 pubmed: 32209449
Laudicella R, Skawran S, Ferraro DA, Muhlematter UJ, Maurer A, Grunig H, et al. Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients. Insights Imaging. 2022;13:75. https://doi.org/10.1186/s13244-022-01217-4 .
doi: 10.1186/s13244-022-01217-4 pubmed: 35426518 pmcid: 9012878
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466–86. https://doi.org/10.1007/s00259-022-06089-w .
doi: 10.1007/s00259-022-06089-w pubmed: 36604326 pmcid: 10027805
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2 .
doi: 10.1007/s00259-012-2298-2 pubmed: 23179945
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer. 1998;82:2256–61. https://doi.org/10.1002/(sici)1097-0142(19980601)82:11%3c2256::aid-cncr22%3e3.0.co;2-s .
doi: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s pubmed: 9610707
Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical Validation of PSMA Expression Measured by (68)Ga-PSMA PET/CT in Primary Prostate Cancer. J Nucl Med. 2018;59:238–43. https://doi.org/10.2967/jnumed.117.195172 .
doi: 10.2967/jnumed.117.195172 pubmed: 28775203
Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941–9. https://doi.org/10.1007/s00259-017-3631-6 .
doi: 10.1007/s00259-017-3631-6 pubmed: 28138747
Roberts MJ, Morton A, Donato P, Kyle S, Pattison DA, Thomas P, et al. (68)Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:477–82. https://doi.org/10.1007/s00259-020-04944-2 .
doi: 10.1007/s00259-020-04944-2 pubmed: 32696091
Ferraro DA, Muehlematter UJ, Garcia Schuler HI, Rupp NJ, Huellner M, Messerli M, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:147–59. https://doi.org/10.1007/s00259-019-04511-4 .
doi: 10.1007/s00259-019-04511-4 pubmed: 31522272
Epstein J, Egevad L, Mahul A, Delahunt B, Srigley J, Humphrey P. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2019;40:244–52.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 10. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. https://doi.org/10.1007/s00259-017-3670-z .
doi: 10.1007/s00259-017-3670-z pubmed: 28283702
Kass G. An Exploratory Technique for Investigating Large Quantities of Categorical Data. J Roy Stat Soc: Ser C (Appl Stat). 1980;29:119–217.
Blockeel H, Struyf J. Efficient Algorithms for Decision Tree Cross-validation. J Mach Learn Res. 2002;3:621–50.
Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET/CT: a real-world study. Theranostics. 2021;11:8396–411. https://doi.org/10.7150/thno.58140 .
doi: 10.7150/thno.58140 pubmed: 34373749 pmcid: 8344003
Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. J Nucl Med. 2016;57:1720–5. https://doi.org/10.2967/jnumed.116.172627 .
doi: 10.2967/jnumed.116.172627 pubmed: 27261520
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021;80:682–9. https://doi.org/10.1016/j.eururo.2021.08.002 .
doi: 10.1016/j.eururo.2021.08.002 pubmed: 34465492
Xue AL, Kalapara AA, Ballok ZE, Levy SM, Sivaratnam D, Ryan A, et al. (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. J Urol. 2022;207:341–9. https://doi.org/10.1097/JU.0000000000002254 .
doi: 10.1097/JU.0000000000002254 pubmed: 34546815
Esen B, Seymen H, Gurses B, Armutlu A, Koseoglu E, Tarim K, et al. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer. Prostate. 2024;84:32–8. https://doi.org/10.1002/pros.24621 .
doi: 10.1002/pros.24621 pubmed: 37661579
Demirci E, Kabasakal L, Sahin OE, Akgun E, Gultekin MH, Doganca T, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86–91. https://doi.org/10.1097/MNM.0000000000000942 .
doi: 10.1097/MNM.0000000000000942 pubmed: 30395048
Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, et al. Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer. J Urol. 2022;207:573–80. https://doi.org/10.1097/JU.0000000000002293 .
doi: 10.1097/JU.0000000000002293 pubmed: 34694140
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-Head Comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med. 2020;61:527–32. https://doi.org/10.2967/jnumed.119.234187 .
doi: 10.2967/jnumed.119.234187 pubmed: 31562225
Huang S, Ong S, McKenzie D, Mirabelli A, Chen DC, Chengodu T, et al. Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00755-2 .
doi: 10.1038/s41391-023-00755-2 pubmed: 38017295
Thie J. Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage. J Nucl Med. 2004;45(9):1431.
pubmed: 15347707
Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63:1644–50. https://doi.org/10.2967/jnumed.121.263448 .
doi: 10.2967/jnumed.121.263448 pubmed: 35301240 pmcid: 9635676
Muehlematter UJ, Schweiger L, Ferraro DA, Hermanns T, Maurer T, Heck MM, et al. Development and external validation of a multivariable [(68)Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:3137–46. https://doi.org/10.1007/s00259-023-06278-1 .
doi: 10.1007/s00259-023-06278-1 pubmed: 37261472 pmcid: 10382335
Santos A, Mattiolli A, Carvalheira JB, Ferreira U, Camacho M, Silva C, et al. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:493–500. https://doi.org/10.1007/s00259-020-04981-x .
doi: 10.1007/s00259-020-04981-x pubmed: 32789680
Wang Z, Zheng A, Li Y, Dong W, Liu X, Yuan W, et al. (18)F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer. Front Oncol. 2021;11: 759053. https://doi.org/10.3389/fonc.2021.759053 .
doi: 10.3389/fonc.2021.759053 pubmed: 34778079 pmcid: 8581554
Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, et al. (68)Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment. J Nucl Med. 2022;63:1822–8. https://doi.org/10.2967/jnumed.122.263897 .
doi: 10.2967/jnumed.122.263897 pubmed: 35512996
Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–38. https://doi.org/10.1007/s00259-021-05245-y .
doi: 10.1007/s00259-021-05245-y pubmed: 33604691 pmcid: 8113168

Auteurs

Timo F W Soeterik (TFW)

Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. timo142@gmail.com.
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. timo142@gmail.com.
ORCID: 0000-0002-0259-8750

Joris G Heetman (JG)

Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.

Rick Hermsen (R)

Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Lieke Wever (L)

Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.

Jules Lavalaye (J)

Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.

Maarten Vinken (M)

Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Clinton D Bahler (CD)

Department of Urology, Indiana University Medical Center, Indianapolis, IN, USA.

Courtney Yong (C)

Department of Urology, Indiana University Medical Center, Indianapolis, IN, USA.

Mark Tann (M)

Department of Radiology and Imaging Sciences, Indiana University Medical Center, Indianapolis, IN, USA.

Claudia Kesch (C)

Department of Urology, University Hospital Essen, Essen German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany.

Robert Seifert (R)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

Tugce Telli (T)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

Peter Ka-Fung Chiu (PK)

S. H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Kwan Kit Wu (KK)

Department of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China.

Fabio Zattoni (F)

Department of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padua, Italy.

Laura Evangelista (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Division of Nuclear Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.

Emma Segalla (E)

Department of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padua, Italy.

Antonio Barone (A)

Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.

Francesco Ceci (F)

Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.

Pawel Rajwa (P)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Medical University of Silesia, Zabrze, Poland.

Giancarlo Marra (G)

University Hospital S Giovanni Battista, Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Turin, Italy.

Elio Mazzone (E)

Division of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Jean-Paul A Van Basten (JA)

Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Harm H E Van Melick (HHE)

Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.

Roderick C N Van den Bergh (RCN)

Department of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.

Giorgio Gandaglia (G)

Division of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Classifications MeSH